Добавил:

Sekretar kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.

Вуз:

Ростовский Государственный Медицинский Университет

Предмет:

Медицина общая

Файл:

Книга_5636_Библиотеки_им_академика_М_И_Перельмана

.pdf

Скачиваний:

Добавлен:

15.09.2026

Размер:

15 Мб

Скачать

☆

<<< < Предыдущая 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 4546 / 5046 47 48 49 50 > Следующая >>>

443

17 Protein Drug Delivery and Formulation Development

https://t.me/med1917

enhances gene replacement therapy in rodent models of retinal degeneration. Mol Ther

14:700–709 Budd JM, Brown JP, Thomas J, Hardwick M, McDonald P, Barber K (2009) A comparison of

sub-Tenon’s with peribulbar anaesthesia in patients undergoing sequential bilateral cataract

surgery. Anaesthesia 64:19–22 Campochiaro PA, Nguyen QD, Shah SM, Klein ML, Holz E, Frank RN, Saperstein DA, Gupta A,

Stout JT, Macko J, DiBartolomeo R, Wei LL (2006) Adenoviral vector-delivered pigment

epithelium-derived factor for neovascular age-related macular degeneration: results of a phase

I clinical trial. Hum Gene Ther 17:167–176 Carlfors J, Edsman K, Petersson R, Jornving K (1998) Rheological evaluation of Gelrite in situ

gels for ophthalmic use. Eur J Pharm Sci 6:113–119 Carpenter JF, Pikal MJ, Chang BS, Randolph TW (1997) Rational design of stable lyophilized

protein formulations: some practical advice. Pharm Res 14:969–975 Cayouette M, Smith SB, Becerra SP, Gravel C (1999) Pigment epithelium-derived factor delays the death

of photoreceptors in mouse models of inherited retinal degenerations. Neurobiol Dis 6:523–532 Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Patel M (2006)

Year 2 efﬁcacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular

age-related macular degeneration. Ophthalmology 113(1508):e1501–e1525 Chang BS, Hershenson S (2002) Practical approaches to protein formulation development. Pharm

Biotechnol 13:1–25 Chang BS, Kendrick BS, Carpenter JF (1996) Surface-induced denaturation of proteins during

freezing and its inhibition by surfactants. J Pharm Sci 85:1325–1330 Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P, de Vos AM, Lowman HB (1999)

matured Fab in complex with antigen. J Mol Biol 293:865–881 Congdon N, O’Colmain B, Klaver CC, Klein R, Munoz B, Friedman DS, Kempen J, Taylor HR,

Mitchell P (2004) Causes and prevalence of visual impairment among adults in the United

States. Arch Ophthalmol 122:477–485 Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D’Amico DJ, Goldbaum M,

Guyer DR, Katz B, Patel M, Schwartz SD (2005) A phase II randomized double-masked trial

of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.

Ophthalmology 112:1747–1757 Delgado C, Francis GE, Fisher D (1992) The uses and properties of PEG-linked proteins. Crit Rev

Ther Drug Carrier Syst 9:249–304 Demetriades AM, Deering T, Liu H, Lu L, Gehlbach P, Packer JD, Mac Gabhann F, Popel AS, Wei LL,

Campochiaro PA (2008) Trans-scleral delivery of antiangiogenic proteins. J Ocul Pharmacol

Ther 24:70–79 DeStafeno JJ, Kim T (2007) Topical bevacizumab therapy for corneal neovascularization. Arch

Ophthalmol 125:834–836 Donati G (2007) Emerging therapies for neovascular age-related macular degeneration: state of the

art. Ophthalmologica 221:366–377 Dratviman-Storobinsky O, Lubin BC, Hasanreisoglu M, Goldenberg-Cohen N (2009) Effect of

subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in

a mouse model of corneal neovascularization. Mol Vis 15:2326–2338 Dunaief JL, Dentchev T, Ying GS, Milam AH (2002) The role of apoptosis in age-related macular

degeneration. Arch Ophthalmol 120:1435–1442 Durairaj C, Shah JC, Senapati S, Kompella UB (2009) Prediction of vitreal half-life based on drug

physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR).

Pharm Res 26:1236–1260 Ehrlich R, Weinberger D, Priel E, Axer-Siegel R (2008) Outcome of bevacizumab (avastin) injection

in patients with age-related macular degeneration and low visual acuity. Retina 28:1302–1307 Einmahl S, Savoldelli M, D’Hermies F, Tabatabay C, Gurny R, Behar-Cohen F (2002) Evaluation

of a novel biomaterial in the suprachoroidal space of the rabbit eye. Invest Ophthalmol Vis Sci

43:1533–1539

444

R. Baid et al.

https://t.me/med1917

Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH,

Quaggin SE (2003) Glomerular-speciﬁc alterations of VEGF-A expression lead to distinct con-

genital and acquired renal diseases. J Clin Invest 111:707–716 Faktorovich EG, Steinberg RH, Yasumura D, Matthes MT, LaVail MM (1990) Photoreceptor

degeneration in inherited retinal dystrophy delayed by basic ﬁbroblast growth factor. Nature

347:83–86 Feher J, Kovacs I, Pacella E, Keresz S, Spagnardi N, Balacco Gabrieli C (2009) Pigment epithelium-

derived factor (PEDF) attenuated capsaicin-induced neurotrophic keratouveitis. Invest Ophthalmol

Vis Sci 50:5173–5180 Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr

Rev 25:581–611 Ferrara N, Gerber HP (2001) The role of vascular endothelial growth factor in angiogenesis. Acta

Haematol 106:148–156 Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab,

an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391–400 Ferrara N, Damico L, Shams N, Lowman H, Kim R (2006) Development of ranibizumab, an anti-

related macular degeneration. Retina 26:859–870 Furrer E, Berdugo M, Stella C, Behar-Cohen F, Gurny R, Feige U, Lichtlen P, Urech DM (2009)

Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-a single-

chain antibody, upon topical administration to the rabbit eye. Invest Ophthalmol Vis Sci

50:771–778 Giganti M, Beer PM, Lemanski N, Hartman C, Schartman J, Falk N (2010) Adverse events after

intravitreal inﬂiximab (remicade). Retina 30:71–80 Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR (2004) Pegaptanib for

neovascular age-related macular degeneration. N Engl J Med 351:2805–2816 Gregory-Evans K, Chang F, Hodges MD, Gregory-Evans CY (2009) Ex vivo gene therapy using

intravitreal injection of GDNF-secreting mouse embryonic stem cells in a rat model of retinal

degeneration. Mol Vis 15:962–973 Group MPS (1991) Laser photocoagulation of subfoveal neovascular lesions in age-related macu-

lar degeneration. Results of a randomized clinical trial. Arch Ophthalmol 109:1220–1231 Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M,

Kampik A (2006) Intravitreal bevacizumab (avastin) therapy for persistent diffuse diabetic

macular edema. Retina 26:999–1005 Harris JM, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov

2:214–221 Hayashi A, Naseri A, Pennesi ME, De Juan E Jr (2009) Subretinal delivery of immunoglobulin G

with gold nanoparticles in the rabbit eye. Jpn J Ophthalmol 53:249–256 Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, Dreyer RF, Gentile RC, Sy JP,

Hantsbarger G, Shams N (2006) Ranibizumab for treatment of neovascular age-related

macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology

113:633–642 Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W (2004) Structure-immunogenicity relation-

ships of therapeutic proteins. Pharm Res 21:897–903 Hoffman H, Pisch-Heberle S (2000) Analytical methods and stability testing of biopharmaceuticals.

In: McNally EJ (ed) Protein formulation and delivery. Informa Healthcare, New York, pp 71–110 Hovorka S, Schoneich C (2001) Oxidative degradation of pharmaceuticals: theory, mechanisms

and inhibition. J Pharm Sci 90:253–269 Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A,

Grifﬁng S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab

plus irinotecan, ﬂuorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med

350:2335–2342 Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra GM (2006) Intravitreal bevacizumab

(avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 142:1054–1056

445

17 Protein Drug Delivery and Formulation Development

https://t.me/med1917

Israelachvili J (1997) The different faces of poly(ethylene glycol). Proc Natl Acad Sci USA

94:8378–8379 Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T (2006) Fluocinolone acetonide

implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter

randomized clinical study. Ophthalmology 113:1020–1027 Jarosch F, Buchner K, Klussmann S (2006) In vitro selection using a dual RNA library that allows

primerless selection. Nucleic Acids Res 34:e86 Jiang C, Moore MJ, Zhang X, Klassen H, Langer R, Young M (2007) Intravitreal injections of

GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma.

Mol Vis 13:1783–1792 Kaiser PK (2005) Verteporﬁn therapy in combination with triamcinolone: published studies inves-

tigating a potential synergistic effect. Curr Med Res Opin 21:705–713 Karalezli A, Borazan M, Akova YA (2008) Intracameral triamcinolone acetonide to control post-

operative inﬂammation following cataract surgery with phacoemulsiﬁcation. Acta Ophthalmol

86:183–187 Khossravi M, Borchardt RT (2000) Chemical pathways of peptide degradation. X: effect of metal-

catalyzed oxidation on the solution structure of a histidine-containing peptide fragment of

human relaxin. Pharm Res 17:851–858 Kim YS, Jones LS, Dong A, Kendrick BS, Chang BS, Manning MC, Randolph TW, Carpenter JF

(2003) Effects of sucrose on conformational equilibria and ﬂuctuations within the native-state

ensemble of proteins. Protein Sci 12:1252–1261 Kompella UB, Lee VHL (1991) Pharmacokinetics of peptide and protein drugs. In: Lee VHL (ed)

Peptide and protein drug delivery. Marcel Dekker, New York, pp 391–484 Kompella UB, Bandi N, Ayalasomayajula SP (2003) Subconjunctival nano- and microparticles

sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression.

Invest Ophthalmol Vis Sci 44:1192–1201 Kompella UB, Sundaram S, Raghava S, Escobar ER (2006) Luteinizing hormone-releasing hor-

mone agonist and transferrin functionalizations enhance nanoparticle delivery in a novel bovine

ex vivo eye model. Mol Vis 12:1185–1198 Kompella UB, Rajendra SK, Lee VHL (2010) Recent advances in ophthalmic drug delivery. Ther

Deliv 1:435–456 Koushik K, Kompella UB (2004) Preparation of large porous deslorelin-PLGA microparticles

with reduced residual solvent and cellular uptake using a supercritical carbon dioxide process.

Pharm Res 21:524–535 Landa G, Amde W, Doshi V, Ali A, McGevna L, Gentile RC, Muldoon TO, Walsh JB, Rosen RB

(2009) Comparative study of intravitreal bevacizumab (avastin) versus ranibizumab (lucentis)

in the treatment of neovascular age-related macular degeneration. Ophthalmologica

223:370–375 LaVail MM, Yasumura D, Matthes MT, Lau-Villacorta C, Unoki K, Sung CH, Steinberg RH

(1998) Protection of mouse photoreceptors by survival factors in retinal degenerations. Invest

Ophthalmol Vis Sci 39:592–602 Lee VH, Robinson JR (1986) Topical ocular drug delivery: recent developments and future chal-

lenges. J Ocul Pharmacol 2:67–108 Lee TW, Robinson JR (2001) Drug delivery to the posterior segment of the eye: some insights

on the penetration pathways after subconjunctival injection. J Ocul Pharmacol Ther 17:

565–572 Lee H, Jang IH, Ryu SH, Park TG (2003) N-terminal site-speciﬁc mono-PEGylation of epidermal

growth factor. Pharm Res 20:818–825 Leveillard T, Mohand-Said S, Lorentz O, Hicks D, Fintz AC, Clerin E, Simonutti M, Forster V,

Cavusoglu N, Chalmel F, Dolle P, Poch O, Lambrou G, Sahel JA (2004) Identiﬁcation and

characterization of rod-derived cone viability factor. Nat Genet 36:755–759 Liang FQ, Dejneka NS, Cohen DR, Krasnoperova NV, Lem J, Maguire AM, Dudus L, Fisher KJ,

Bennett J (2001) AAV-mediated delivery of ciliary neurotrophic factor prolongs photoreceptor

survival in the rhodopsin knockout mouse. Mol Ther 3:241–248

446

R. Baid et al.

https://t.me/med1917

Liu H, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J (2008) Heterogeneity of monoclonal antibodies.

J Pharm Sci 97:2426–2447 Machida S, Chaudhry P, Shinohara T, Singh DP, Reddy VN, Chylack LT Jr, Sieving PA, Bush RA

(2001) Lens epithelium-derived growth factor promotes photoreceptor survival in light-

damaged and RCS rats. Invest Ophthalmol Vis Sci 42:1087–1095 May DR, Klein ML, Peyman GA (1976) A prospective study of xenon arc photocoagulation for

central retinal vein occlusion. Br J Ophthalmol 60:816–818 Mehvar R (2000) Modulation of the pharmacokinetics and pharmacodynamics of proteins by poly-

ethylene glycol conjugation. J Pharm Pharm Sci 3:125–136 Mori K, Gehlbach P, Ando A, McVey D, Wei L, Campochiaro PA (2002) Regression of ocular

neovascularization in response to increased expression of pigment epithelium-derived factor.

Invest Ophthalmol Vis Sci 43:2428–2434 Moshfeghi AA, Rosenfeld PJ, Puliaﬁto CA, Michels S, Marcus EN, Lenchus JD, Venkatraman AS

(2006) Systemic bevacizumab (avastin) therapy for neovascular age-related macular degenera-

tion: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology

113(2002):e2001–e2012 Nagpal M, Marlecha S, Nagpal K (2010) Comparison of laser photocoagulation for diabetic retin-

opathy using 532-nm standard laser versus multispot pattern scan laser. Retina 30:452–458 Ng EWM, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP (2006) Pegaptanib, a

targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5:123–132 Nguyen QD, Shah SM, Haﬁz G, Quinlan E, Sung J, Chu K, Cedarbaum JM, Campochiaro PA

(2006) A phase I trial of an IV-administered vascular endothelial growth factor trap for treat-

ment in patients with choroidal neovascularization due to age-related macular degeneration.

Ophthalmology 113:1522; e1521–1522; e1514 Nguyen QD, Shah SM, Browning DJ, Hudson H, Sonkin P, Hariprasad SM, Kaiser P, Slakter JS,

Haller J, Do DV, Mieler WF, Chu K, Yang K, Ingerman A, Vitti RL, Berliner AJ, Cedarbaum JM,

Campochiaro PA (2009) A phase I study of intravitreal vascular endothelial growth factor

trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology

116(11):2141–2148 Nie Y, Zhang X, Wang X, Chen J (2006) Preparation and stability of N-terminal mono-PEGylated

recombinant human endostatin. Bioconjug Chem 17:995–999 Nimjee SM, Rusconi CP, Harrington RA, Sullenger BA (2005) The potential of aptamers as anti-

coagulants. Trends Cardiovasc Med 15:41–45 Nissen NN, Polverini PJ, Koch AE, Volin MV, Gamelli RL, DiPietro LA (1998) Vascular endothe-

lial growth factor mediates angiogenic activity during the proliferative phase of wound healing.

Am J Pathol 152:1445–1452 Olsen TW, Edelhauser HF, Lim JI, Geroski DH (1995) Human scleral permeability. Effects of age,

cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci

36:1893–1903 Owen GR, Brooks AC, James O, Robertson SM (2007) A novel in

human dosing to determine the distribution of antibiotics in ocular tissues. J Ocul Pharmacol

Ther 23:335–342 Prausnitz MR, Noonan JS (1998) Permeability of cornea, sclera, and conjunctiva: a literature anal-

ysis for drug delivery to the eye. J Pharm Sci 87:1479–1488 Qiu G, Seiler MJ, Mui C, Arai S, Aramant RB, De Juan E Jr, Sadda S (2005) Photoreceptor dif-

ferentiation and integration of retinal progenitor cells transplanted into transgenic rats. Exp Eye

Res 80:515–525 Raghava S, Hammond M, Kompella UB (2004) Periocular routes for retinal drug delivery. Expert

Opin Drug Deliv 1:99–114 Raghuram A, Saravanan VR, Narendran V (2007) Intracameral injection of bevacizumab (avastin)

to treat anterior chamber neovascular membrane in a painful blind eye. Indian J Ophthalmol

55:460–462 Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N (2008)

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related

macular degeneration: PIER study year 1. Am J Ophthalmol 145:239–248

vivo rabbit model that mimics

447

17 Protein Drug Delivery and Formulation Development

https://t.me/med1917

Rich RM, Rosenfeld PJ, Puliaﬁto CA, Dubovy SR, Davis JL, Flynn HW Jr, Gonzalez S, Feuer WJ,

Lin RC, Lalwani GA, Nguyen JK, Kumar G (2006) Short-term safety and efﬁcacy of intravit-

real bevacizumab (avastin) for neovascular age-related macular degeneration. Retina

26:495–511 Rosenfeld PJ, Fung AE, Puliaﬁto CA (2005) Optical coherence tomography ﬁndings after an intra-

vitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlu-

sion. Ophthalmic Surg Lasers Imaging 36:336–339 Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab

for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431 Saishin Y, Saishin Y, Takahashi K, Lima e Silva R, Hylton D, Rudge JS, Wiegand SJ, Campochiaro PA

(2003) VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced

breakdown of the blood-retinal barrier. J Cell Physiol 195:241–248 Schmid-Kubista KE, Krebs I, Gruenberger B, Zeiler F, Schueller J, Binder S (2009) Systemic

bevacizumab (avastin) therapy for exudative neovascular age-related macular degeneration.

The BEAT-AMD-study. Br J Ophthalmol 93:914–919 Schmidt-Erfurth U, Miller J, Sickenberg M, Bunse A, Laqua H, Gragoudas E, Zografos L,

Birngruber R, van den Bergh H, Strong A, Manjuris U, Fsadni M, Lane AM, Piguet B, Bressler NM

(1998) Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angio-

graphic examples. Graefes Arch Clin Exp Ophthalmol 236:365–374 Shelke NB, Kadam R, Tyagi P, Rao VR, Kompella UB (2011) Intravitreal poly(l-lactide) micropar-

ticles sustain retinal and choroidal delivery of TG-0054, a hydrophilic drug intended for

neovascular diseases. Drug Del Transl Res 1. doi: 10.1007/s13346-13010-10009-13348 Sheu SJ, Bee YS, Ma YL, Liu GS, Lin HC, Yeh TL, Liou JC, Tai MH (2009) Inhibition of choroi-

dal neovascularization by topical application of angiogenesis inhibitor vasostatin. Mol Vis

15:1897–1905 Sieving PA, Caruso RC, Tao W, Coleman HR, Thompson DJ, Fullmer KR, Bush RA (2006) Ciliary

neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by

encapsulated cell intraocular implants. Proc Natl Acad Sci USA 103:3896–3901 Simpson RJ (2010) Stabilization of proteins for storage. Cold Spring Harb Protoc. doi:10.1101/

pdb.top1179 Singh SR, Grossniklaus HE, Kang SJ, Edelhauser HF, Ambati BK, Kompella UB (2009)

Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF

intraceptor gene delivery to laser-induced CNV. Gene Ther 16:645–659 Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J,

Fisher YL, Cooney MJ (2006) Intravitreal bevacizumab treatment of choroidal neovasculariza-

tion secondary to age-related macular degeneration. Retina 26:383–390 Spencer WH (1953) Pseudomonas aeruginosa infections of the eye. Calif Med 79:438–443 Srebalus Barnes CA, Lim A (2007) Applications of mass spectrometry for the structural character-

ization of recombinant protein pharmaceuticals. Mass Spectrom Rev 26:370–388 Steele FR, Chader GJ, Johnson LV, Tombran-Tink J (1993) Pigment epithelium-derived factor:

neurotrophic activity and identiﬁcation as a member of the serine protease inhibitor gene fam-

ily. Proc Natl Acad Sci USA 90:1526–1530 Stewart MW, Rosenfeld PJ (2008) Predicted biological activity of intravitreal VEGF trap. Br J

Ophthalmol 92:667–668 Takahashi H, Shibuya M (2005) The vascular endothelial growth factor (VEGF)/VEGF receptor

system and its role under physiological and pathological conditions. Clin Sci (Lond)

109:227–241 Takeda AL, Colquitt J, Clegg AJ, Jones J (2007) Pegaptanib and ranibizumab for neovascular age-

related macular degeneration: a systematic review. Br J Ophthalmol 91:1177–1182 Tang X, Pikal MJ (2004) Design of freeze-drying processes for pharmaceuticals: practical advice.

Pharm Res 21:191–200 Tao W, Wen R, Goddard MB, Sherman SD, O’Rourke PJ, Stabila PF, Bell WJ, Dean BJ, Kauper KA,

Budz VA, Tsiaras WG, Acland GM, Pearce-Kelling S, Laties AM, Aguirre GD (2002)

Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models

of retinitis pigmentosa. Invest Ophthalmol Vis Sci 43:3292–3298

448 R. Baid et al.

https://t.me/med1917

Thanos CG, Bell WJ, O’Rourke P, Kauper K, Sherman S, Stabila P, Tao W (2004) Sustained secre-

tion of ciliary neurotrophic factor to the vitreous, using the encapsulated cell therapy-based

NT-501 intraocular device. Tissue Eng 10:1617–1622 Travis GH (1998) Mechanisms of cell death in the inherited retinal degenerations. Am J Hum

Genet 62:503–508 Tsinontides SC, Rajniak P, Pham D, Hunke WA, Placek J, Reynolds SD (2004) Freeze drying –

principles and practice for successful scale-up to manufacturing. Int J Pharm 280:1–16 Veronese FM (2001) Peptide and protein PEGylation: a review of problems and solutions.

Biomaterials 22:405–417 Veronese FM, Mero A (2008) The impact of PEGylation on biological therapies. BioDrugs

22:315–329 Veronese FM, Sacca B, Polverino de Laureto P, Sergi M, Caliceti P, Schiavon O, Orsolini P (2001)

New PEGs for peptide and protein modiﬁcation, suitable for identiﬁcation of the PEGylation

site. Bioconjug Chem 12:62–70 Wang JH, Tam SC, Huang H, Ouyang DY, Wang YY, Zheng YT (2004) Site-directed PEGylation

of trichosanthin retained its anti-HIV activity with reduced potency in

Res Commun 317:965–971 Weigert G, Michels S, Sacu S, Varga A, Prager F, Geitzenauer W, Schmidt-Erfurth U (2008)

Intravitreal bevacizumab (avastin) therapy versus photodynamic therapy plus intravitreal tri-

amcinolone for neovascular age-related macular degeneration: 6-month results of a prospec-

tive, randomised, controlled clinical study. Br J Ophthalmol 92:356–360 Wenzel A, Grimm C, Samardzija M, Reme CE (2005) Molecular mechanisms of light-induced

photoreceptor apoptosis and neuroprotection for retinal degeneration. Prog Retin Eye Res

24:275–306 Wormald R, Evans J, Smeeth L, Henshaw K (2007) Photodynamic therapy for neovascular age-

related macular degeneration. Cochrane Database Syst Rev (3):CD002030 Xuan B, McClellan DA, Moore R, Chiou GC (2005) Alternative delivery of insulin via eye drops.

Diabetes Technol Ther 7:695–698 Yamamoto A, Luo AM, Dodda-Kashi S, Lee VH (1989) The ocular route for systemic insulin

delivery in the albino rabbit. J Pharmacol Exp Ther 249:249–255 Yamaoka T, Tabata Y, Ikada Y (1994) Distribution and tissue uptake of poly(ethylene glycol) with

different molecular weights after intravenous administration to mice. J Pharm Sci 83:601–606 Yoon S, Kim Y, Shim H, Chung J (2010) Current perspectives on therapeutic antibodies. Biotechnol

Bioprocess Eng 15:709–715

vitro. Biochem Biophys